Enantiospecific Pharmacogenomics of Fluvastatin

Päivi Hirvensalo¹,²,³, Aleksi Tornio¹,²,³, Mikko Neuvonen¹,²,³, Wilma Kiander⁴, Heidi Kidron⁴, Maria Paile-Hyvärinen¹,²,³, Tuija Tapaninen¹,²,³, Janne T. Backman¹,²,³ and Mikko Niemi¹,²,³,*

The aim of this study was to investigate how variability in multiple genes related to pharmacokinetics affects fluvastatin exposure. We determined fluvastatin enantiomer pharmacokinetics and sequenced 379 pharmacokinetic genes in 200 healthy volunteers. CYP2C9*3 associated with significantly increased area under the plasma concentration-time curve (AUC) of both 3R,5S-fluvastatin and 3S,5R-fluvastatin (by 67% and 94% per variant allele copy, \( P = 3.77 \times 10^{-9} \) and \( P = 3.19 \times 10^{-12} \)). In contrast, SLC01B1 c.521T>C associated with increased AUC of active 3R,5S-fluvastatin only (by 34% per variant allele copy; \( P = 8.15 \times 10^{-8} \)). A candidate gene analysis suggested that CYP2C9*2 also affects the AUC of both fluvastatin enantiomers and that SLCO2B1 single-nucleotide variations may affect the AUC of 3S,5R-fluvastatin. Thus, SLCO transporters have enantiospecific effects on fluvastatin pharmacokinetics in humans. Genotyping of both CYP2C9 and SLC01B1 may be useful in predicting fluvastatin efficacy and myotoxicity.

Fluvastatin is a 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitor, which is used in the treatment of hypercholesterolemia. It is a racemic mixture of two enantiomers, of which 3R,5S-fluvastatin is 30 times more active than 3S,5R-fluvastatin.¹

Fluvastatin is extensively metabolized via cytochrome P450 (CYP) 2C9.²,³ In vitro also CYP3A4, CYP2C8, and possibly CYP2D6 and CYP1A1 contribute to fluvastatin metabolism.² In addition, fluvastatin is a substrate of several drug transporters, including organic anion transporting polypeptides (OATP) 1B1, 1B3, 2B1, breast cancer resistance protein, multidrug resistance-associated protein 2, and sodium-dependent taurocholate cotransporting polypeptide.⁴–⁸

High interindividual variability exists in the pharmacokinetics of fluvastatin. The decreased-function CYP2C9*3 (c.1075A>C, p.Ile359Leu, rs1057910) allele⁹,¹⁰ has been associated with markedly increased plasma concentrations of both fluvastatin enantiomers.¹¹ Furthermore, the decreased-function ABCG2 c.421C>A (p.Gln141Lys, rs2231142) variant¹²–¹⁵ has been associated with markedly increased plasma concentrations of racemic fluvastatin.¹⁴ On the other hand, the decreased-function SLC01B1 c.521T>C...
Table 1 Results of the stepwise forward linear regression analysis of the effects of 46,064 SNVs in 379 genes on fluvastatin pharmacokinetics

| Pharmacokinetic variable | dbSNP ID | Gene | Location | Nucleotide change | MAF | Average (%) | 90% CI | P value |
|--------------------------|----------|------|----------|-------------------|-----|--------------|--------|--------|
| 3R,5S-fluvastatin        |          |      |          |                   |     |              |        |        |
| AUC0–∞rs77760615         | 1. rs77760615 CYP2C9 | Upstream | c.-5813A>G | 0.072 | 69.7 | 49.0, 93.2 | 2.16 × 10−10 |
|                          | 2. rs58310495 SLCO1B1 | Intron 10/14 | c.1332-1091C>T | 0.29 | 34.4 | 24.9, 44.6 | 3.07 × 10−10 |
| Cmax                    | —        | —    | —        | —                 | —   | —            | —      | —      |
| t½                      | —        | —    | —        | —                 | —   | —            | —      | —      |
| Total fluvastatin AUC0–∞ | rs77760615 CYP2C9 | Upstream | c.-5813A>G | 0.072 | 88.9 | 62.8, 119.1 | 2.93 × 10−11 |
| 3R,5S/3S,5R AUC0–∞ ratio | 1. rs4149056 SLCO1B1 | Exon 6/15 | c.521T>C | 0.22 | 23.3 | 19.6, 27.2 | 1.30 × 10−22 |
|                          | 2. rs12367888 SLCO1B1 | Intron 7/14 | c.728-2859G>A | 0.16 | —11.6 | —14.7, —8.3 | 5.24 × 10−8 |

AUC0–∞, area under the plasma concentration-time curve from 0 hour to infinity; CI, confidence interval; Cmax, peak plasma concentration; dbSNP, National Center for Biotechnology Information Short Genetic Variations database; MAF, minor allele frequency; SNV, single-nucleotide variation; t½, elimination half-life; —, not applicable.

*Per variant allele copy.

(results of 379 pharmacokinetic genes using massive parallel sequencing.)

(rs12367888 remained statistically significantly associated with the AUC0–∞ of 3R,5S-fluvastatin and 3S,5R-fluvastatin after a 40 mg oral dose of racemic fluvastatin in 200 healthy volunteers and fully sequenced 379 pharmacokinetic genes using massive parallel sequencing).

RESULTS
Fluvastatin pharmacogenomics

Among the 200 healthy volunteers, the areas under the plasma concentration-time curve from 0 hour to infinity (AUC0–∞) of 3R,5S-fluvastatin and 3S,5R-fluvastatin varied 16- and 19-fold, respectively (Table S1). A single-nucleotide variation (SNV), rs77760615, located upstream of CYP2C9 showed the strongest association with the pharmacokinetics of both fluvastatin enantiomers (Figure 1). The AUC0–∞ of 3R,5S-fluvastatin was 70% (P = 2.16 × 10−10) and that of 3S,5R-fluvastatin was 89% (P = 2.93 × 10−11) larger per copy of the variant allele. After adjusting for this variant, an intronic triallelic haplotype have not affected fluvastatin pharmacokinetics).21,24 Comprehensive studies evaluating the effects of variants in multiple genes on fluvastatin pharmacokinetics have not been conducted previously. Therefore, the aim of this study was to investigate how variability in pharmacokinetic genes affects fluvastatin exposure. We determined the pharmacokinetics of 3R,5S-fluvastatin and 3S,5R-fluvastatin after a 40 mg oral dose of racemic fluvastatin in 200 healthy volunteers and fully sequenced 379 pharmacokinetic genes using massive parallel sequencing.

In agreement with these results, also the total 3R,5S+3S,5R-fluvastatin AUC0–∞ associated significantly with the Cmax or t½ of total fluvastatin.

To further identify the genetic factors that differently affect the two enantiomers, we investigated the associations of the genetic variants with 3R,5S/3S,5R-fluvastatin AUC0–∞. The AUC0–∞ ratio was significantly associated with the SLCO1B1 missense SNV rs58310495 (P = 2.16 × 10−10) and that of 3S,5R-fluvastatin was 89% (P = 2.93 × 10−11). After adjusting for this variant, an intronic triallelic SLCO1B1 SNV rs12367888 remained significantly associated with the AUC0–∞ ratio. The ratio was 12% lower per copy of the rs12367888 A-allele (P = 5.24 × 10−8).

Linkage disequilibrium and haplotype analysis

In order to identify the causative SNVs underlying the associations of CYP2C9 rs77760615 and SLCO1B1 rs58310495 and rs12367888, we next investigated the linkage disequilibrium of these variants with missense SNVs in the respective genes. The rs77760615 SNV was in a complete linkage disequilibrium (r² = 1, P = 7.04 × 10−44) with the c.1075A>C (p.Ile359Leu, rs1057910) missense SNV, defining the CYP2C93 allele (Figure 2a). The SLCO1B1 rs58310495 SNV was strongly linked with the SLCO1B1 missense variants c.521T>C (P = 5.78 × 10−32) and c.388A>G (P = 5.18 × 10−19) (Figure 2b). Moreover, the A allele of the triallelic rs12367888 SNV was relatively strongly linked with the missense variants c.463C>A (P = 0.27, r² = 0.75, 95% CI: 0.20–0.84) and c.388A>G (P = 0.25, r² = 0.32, 95% CI: 0.17–0.46) (Figure 2b). In agreement with these results, also the total 3R,5S+3S,5R-fluvastatin AUC0–∞ associated significantly with the CYP2C9 upstream variant rs77760615 (Table 1). The AUC0–∞ was 82% larger per copy of the variant allele (P = 8.50 × 10−11). After adjusting for this variant, no other variants remained statistically significantly associated with the total fluvastatin AUC0–∞. The investigated variants had no significant effect on the Cmax or t½ of total fluvastatin.

Previous studies have suggested that the functional effects of SLCO1B1 SNVs may depend on the combinations of SNVs in the same haplotype.17–23 We therefore computed SLCO1B1 haplotypes using missense variations and the noncoding rs58310495
and rs12367888 SNVs (Figure 2c). The rs58310495 variant was found to be present in all SLCO1B1*5 and *15 haplotypes and in 63% of the *1B haplotypes, but not in *14 or *35. The rs12367888 A allele was present in all SLCO1B1*14 and *35 haplotypes, and in 24% of the *1B haplotypes.

Candidate gene analysis
To mitigate the risk of false negatives due to the conservative Bonferroni correction used in the primary analysis, we next carried out a candidate gene analysis without correction for multiple testing, including missense and functional variants with minor
allele frequencies of ≥ 0.01 in genes involved in fluvastatin pharmacokinetics (Table S2). The candidate gene analysis focused on AUC_{0-∞}, because it describes total exposure and is likely the best surrogate for drug response. In this analysis, CYP2C9*3 was associated with a 67% (P = 3.77 × 10^{-9}), SLC01B1 c.521T>C with a 34% (P = 8.15 × 10^{-8}), and CYP2C9*2 (rs1799853, c.430C>T, p.Arg144Cys) with a 23% (P = 0.00213) increased AUC_{0-∞} of 3R,5S-fluvastatin per copy of each variant allele (Table 2). The

Figure 2 Linkage disequilibrium of (a) CYP2C9 and (b) SLC01B1 missense and top noncoding SNVs. (c) SLC01B1 haplotypes (MAF ≥0.01) inferred with missense and top noncoding SLC01B1 SNVs. Intrinsic nucleotide changes are depicted in yellow and blue, and missense variations in red. MAF, minor allele frequency; SNV, single-nucleotide variation. [Colour figure can be viewed at wileyonlinelibrary.com]

| Allele | rs | Frequency | Haplotype | n | Frequency | Haplotype group |
|--------|----|-----------|-----------|---|-----------|----------------|
| A      | C  | T         | G         | C | A        | 216            |
| G      | C  | T         | G         | C | A        | 5              |
| G      | C  | T         | G         | T | A        | 4              |
| G      | C  | T         | A         | C | A        | 10             |
| G      | A  | T         | A         | C | A        | 22             |
| G      | C  | C         | T         | A | T        | 76             |
| A      | C  | C         | T         | T | A        | 11             |

*MAF* = minor allele frequency.
**Table 2** Results of the candidate gene analysis on 3R,5S-fluvastatin and 3S,5R-fluvastatin AUC₀⁻∞, total fluvastatin AUC₀⁻∞, and 3R,5S/3S,5R-fluvastatin AUC₀⁻∞ ratio

| Pharmacokinetic variable | Covariate/SNV | Average (%) | 90% CI   | P value       | Bonferroni-adjusted P value | Adjusted R² for each step |
|--------------------------|--------------|-------------|----------|---------------|-----------------------------|--------------------------|
| 3R,5S-fluvastatin AUC₀⁻∞ | BSA          | −19.9       | −23.4, −16.2 | 3.10 × 10⁻¹⁴ | —                           | 0.24                     |
|                         | CYP2C9*3 (rs1057910) | 66.7 | 45.4, 91.0 | 3.77 × 10⁻⁹ | 1.01 × 10⁻⁷ | 0.36                     |
|                         | SLC01B1 c.521T>C (rs4149056) | 34.2 | 23.0, 46.4 | 8.15 × 10⁻⁸ | 2.20 × 10⁻⁶ | 0.44                     |
|                         | CYP2C9*2 (rs1799853) | 22.7 | 10.1, 36.7 | 0.00213 | 0.0575 | 0.46                     |
| 3S,5R-fluvastatin AUC₀⁻∞ | BSA          | −20.7       | −24.4, −16.8 | 1.06 × 10⁻¹³ | —                           | 0.20                     |
|                         | CYP2C9*3 (rs1057910) | 93.6 | 67.2, 124.2 | 3.19 × 10⁻¹² | 8.61 × 10⁻¹¹ | 0.35                     |
|                         | CYP2C9*2 (rs1799853) | 29.1 | 14.9, 45.1 | 3.94 × 10⁻⁴ | 0.0106 | 0.38                     |
|                         | SLC02B1 c.601G>A (rs35199625) | 45.2 | 10.6, 90.7 | 0.0246 | 0.664 | 0.39                     |
|                         | SLC02B1 c.1457C>T (rs2306168) | −21.7 | −35.0, −5.7 | 0.0306 | 0.825 | 0.40                     |
| Total fluvastatin AUC₀⁻∞ | BSA          | −19.7       | −23.3, −16.0 | 1.75 × 10⁻¹³ | —                           | 0.23                     |
|                         | CYP2C9*3 (rs1057910) | 75.4 | 52.4, 101.8 | 3.17 × 10⁻¹⁰ | 1.00 × 10⁻⁸ | 0.37                     |
|                         | SLC01B1 c.521T>C (rs4149056) | 20.4 | 10.1, 31.7 | 7.54 × 10⁻⁴ | 0.0203 | 0.40                     |
|                         | CYP2C9*2 (rs1799853) | 25.4 | 12.2, 40.2 | 9.63 × 10⁻⁴ | 0.0260 | 0.43                     |
| 3R,5S/3S,5R AUC₀⁻∞ ratio | SLC01B1 c.521T>C (rs4149056) | 28.2 | 23.7, 32.8 | 4.37 × 10⁻²⁴ | 1.18 × 10⁻²² | 0.41                     |
|                         | SLC01B1 c.1929A>C (rs34671512) | −15.6 | −20.0, −11.0 | 4.52 × 10⁻⁷ | 1.22 × 10⁻⁵ | 0.48                     |
|                         | SLC01B1 c.463C>A (rs11045819) | −10.4 | −14.1, −6.6 | 2.62 × 10⁻⁵ | 7.08 × 10⁻⁴ | 0.53                     |
|                         | CYP2C9*3 (rs1057910) | −10.7 | −14.7, −6.6 | 4.41 × 10⁻⁵ | 0.00119 | 0.55                     |
|                         | SLC02B1 c.1457C>T (rs2306168) | 8.8 | 2.9, 15.1 | 0.0134 | 0.361 | 0.56                     |
|                         | SLC02B1 c.935G>A (rs12422149) | −5.1 | −8.5, −1.5 | 0.0221 | 0.597 | 0.57                     |
|                         | SLC01B3 c.699G>A (rs7311358) | −4.0 | −7.2, −0.8 | 0.0434 | 1.173 | 0.58                     |

AUC₀⁻∞ of 3S,5R-fluvastatin was 94% (P = 3.19 × 10⁻¹²), 29% (P = 3.94 × 10⁻⁴), and 45% (P = 0.0246) larger per copy of CYP2C9*3, CYP2C9*2, and SLC02B1 c.601G>A (p.Val201Met, rs35199625) variant allele, respectively, and 22% (P = 0.0306) smaller per copy of the SLC02B1 c.1457C>T (p.Ser486Phe, rs2306168) variant allele. When the candidate gene analysis

AUC₀⁻∞, area under the plasma concentration-time curve from 0 hour to infinity; BSA, body surface area; CI, confidence interval; MAF, minor allele frequency; SNV, single nucleotide variation; —, not applicable.

*Per 10% increase in BSA or per variant allele copy. aCompletely linked with SLC01B3 missense SNV c.334T>G (rs4149117).
was performed with SLCO1B1 haplotypes instead of SNVs, the SLCO1B1*I5 haplotype was associated with 3R,5S-fluvastatin AUC_{0→∞} (Table S3). None of the SLCO1B1 haplotypes associated with 3S,5R-fluvastatin AUC_{0→∞}.

The total fluvastatin AUC_{0→∞} was 75% (P = 3.17 × 10^{-10}), 20% (P = 7.54 × 10^{-7}), and 25% (P = 9.63 × 10^{-8}) larger per copy of the CYP2C9*3, SLCO1B1 c.521T>C, and CYP2C9*2 variant allele, respectively (Table 2). The 3R,5S/3S,5R-fluvastatin AUC_{0→∞} ratio showed significant association with variants in the SLCO1B1, CYP2C9, SLCO2B1, and SLCO1B3 genes. Of the SLCO1B1 haplotypes, SLCO1B1*I5 was associated with increased total fluvastatin AUC_{0→∞}; SLCO1B1*5 and *15 were associated with increased, and the *14 and *35 haplotypes with decreased, 3S,5S/3S,5R-fluvastatin AUC_{0→∞} ratio (Table S3).

To predict the relative effects of combinations of CYP2C9 and SLCO1B1 or SLCO2B1 genotypes on fluvastatin and fluvastatin enantiomer exposures, we calculated genotype scores (GS) using the following equations based on the candidate gene linear regression models:

\[ GS_{3R,5S-\text{fluvastatin}} = 1.63^{(\text{CYP2C9}\,3)} \times 1.34^{(\text{SLCO1B1}\, c.521\, T)} \times 1.23^{(\text{CYP2C9}\, 2)} \]

\[ GS_{3S,5R-\text{fluvastatin}} = 1.94^{(\text{CYP2C9}\,3)} \times 1.29^{(\text{CYP2C9}\, 2)} \times 1.45^{(\text{SLCO2B1}\, c.691\, A)} \times 0.78^{(\text{SLCO2B1}\, c.1457\, T)} \]

\[ GS_{\text{total fluvastatin}} = 1.75^{(\text{CYP2C9}\, 3)} \times 1.20^{(\text{SLCO1B1}\, c.521\, C)} \times 1.25^{(\text{CYP2C9}\, 2)} \]

where \( n \) is the number of variant alleles (0, 1, or 2).

The genotype scores predict the fold differences in AUCs between carriers of different genotype combinations and non-carriers (Table 3, Figure 3). A total of 12%, 2.0%, and 9.5% of the study population had GS predicting more than twofold increased AUCs of 3R,5S-fluvastatin, 3S,5R-fluvastatin, and total fluvastatin, respectively.

**Fluvastatin transport by OATP1B1 and metabolism in vitro**

To mechanistically validate the findings, we investigated the transport of fluvastatin enantiomers in OATP1B1-transfected human embryonic kidney 293 cells, expressing either the reference or the c.521T>C variant SLCO1B1. Both 3R,5S-fluvastatin and 3S,5R-fluvastatin were substrates of reference OATP1B1, as indicated by 7.3-fold and 4.1-fold higher cellular uptake at 0.5 μM, and 2.5-fold and 2.5-fold higher at 4 μM in OATP1B1-transfected cells than in mock-transfected cells (P < 0.001). The c.521T>C SNV reduced the uptake of both enantiomers to 7% of the control (P < 10^{-5}) (Figure 4).

We also investigated the metabolism of fluvastatin enantiomers by human liver microsomes (HLM), and recombinant CYP2C9.1, CYP2C9.2, and CYP2C9.3 enzymes. The microsomal intrinsic clearance (CL_{int,HLM}) of 3R,5S-fluvastatin was 39 μL/minute/mg protein and that of 3S,5R-fluvastatin was 33 μL/minute/mg protein (P = 1.32 × 10^{-4}, Figure 4). The CYP2C9 inhibitor sulfaphenazole inhibited the CL_{int,HLM} of 3R,5S-fluvastatin by 51% (P = 2.14 × 10^{-9}) and that of 3S,5R-fluvastatin by 69% (P = 1.60 × 10^{-7}). Fluvastatin enantiomers were similarly metabolized by CYP2C9.1 (P = 0.455). The CL_{int} of 3S,5S-fluvastatin was reduced by 38% (P = 0.0132) and 65% (P = 0.00273), and that of 3S,5R-fluvastatin by 25% (P = 0.00620) and 84% (P = 4.95 × 10^{-12}) by recombinant CYP2C9.2 and CYP2C9.3, respectively, as compared with CYP2C9.1.

**DISCUSSION**

These results show that genetic variation in CYP2C9 strongly affects the pharmacokinetics of both fluvastatin enantiomers. SLCO1B1 variants, on the other hand, affect the pharmacokinetics of 3R,5S-fluvastatin only. Moreover, the candidate gene approach suggests that SLCO2B1 variants may affect the plasma concentrations of 3S,5R-fluvastatin. Taken together, although the activity of CYP2C9 strongly affects the exposures to both fluvastatin enantiomers, the effects of SLCO transporters are enantiospecific.

The CYP2C9*3 and CYP2C9*2 alleles are known to impair the function of CYP2C9.9,10,26 The finding that CYP2C9*3 had a markedly larger effect than CYP2C9*2 in vivo is in line with our in vitro results showing a larger effect of CYP2C9*3 than CYP2C9*2 on fluvastatin metabolism. In a previous study, CYP2C9*3 was associated with increased AUC of both fluvastatin enantiomers, whereas the effect of CYP2C9*2 was not significant.11 However, the number of participants in that study was relatively small. Nevertheless, our results indicate that both CYP2C9*3 and *2 affect the pharmacokinetics of both fluvastatin enantiomers.

The finding that CYP2C9*3 had a larger effect on the AUC of 3S,5R-fluvastatin than 3S,5S-fluvastatin could be explained by different contributions of CYP2C9 to the elimination of the enantiomers, enantiomer-dependent effect of CYP2C9*3, or both. Our in vitro results support both of these hypotheses, as the CYP2C9 inhibitor sulfaphenazole and recombinant CYP2C9.3 reduced the metabolism of 3S,5R-fluvastatin more than that of 3R,5S-fluvastatin.

In addition to CYP2C9 variants, an intronic SLCO1B1 rs58310495 SNV was associated with significantly increased AUC of 3S,5S-fluvastatin. This SNV is strongly linked with the decreased-function SLCO1B1 c.521T>C variant,16–23 which suggests that the association is due to c.521T>C. Interestingly, no associations with SLCO1B1 variants were present for 3S,5R-fluvastatin even in the candidate gene analysis with no correction for multiple testing (effect size 6.5% per copy of the c.521C allele, P = 0.259). Accordingly, the c.521T>C variant was associated with significantly increased 3R,5S/3S,5R-fluvastatin AUC ratio. Thus, our results demonstrate that the effect of the SLCO1B1 genotype on fluvastatin pharmacokinetics is enantiospecific.

In addition to SLCO1B1 c.521T>C, the A allele of a triallelic intrinsic SLCO1B1 SNV (rs12367888) was associated with significantly decreased 3R,5S/3S,5R-fluvastatin AUC ratio. Similarly, in the candidate gene analysis, the missense c.463C>A and c.1929A>C SNVs, which are strongly linked with the rs12367888 A allele, significantly decreased the AUC ratio. As the SLCO1B1 genotype has an enantiospecific effect on 3S,5S-fluvastatin, the decreased AUC ratio is likely due to increased OATP1B1 activity.
In line with this, the *SLCO1B1*^*14^ (containing c.463C>A) and *35^ (containing c.1929A>C) haplotypes have previously been associated with increased hepatic expression of OA TP1B1 and increased clearance of the OA TP1B1 substrate methotrexate.\(^{28}\) *SLCO1B1*^*14^ has also been associated with a decreased AUC of atorvastatin\(^{27}\) and c.463C>A with decreased plasma concentrations of rifampin.\(^{29}\)

Although *SLCO1B1* c.521T>C markedly raises the plasma concentrations of many statins\(^{17-23}\) the AUC of total fluvastatin was only nonsignificantly (by 19%) increased in c.521CC.

---

### Table 3 Pharmacokinetic variables of 3R,5S-fluvastatin, 3S,5R-fluvastatin, and total fluvastatin grouped by genotype scores\(^a\)

|                      | C\(_{\text{max}}\) (ng/mL) | T\(_{\text{max}}\) (hour) | AUC\(_{0-\infty}\) (ng/hour/mL) | t\(_{1/2}\) (hour) |
|----------------------|-----------------------------|---------------------------|-------------------------------|------------------|
| **3R,5S-fluvastatin** |                             |                           |                               |                  |
| Genotype score ≥0.80, ≤1.25\(^b\) |                             |                           |                               |                  |
| Geometric mean (CV%) | 124 (72%)                   | 1 (0.5–5)                 | 172 (46%)                     | 1.9 (33%)        |
| Genotype score > 1.25, < 2.00 |                             |                           |                               |                  |
| Geometric mean (CV%) | 183 (65%)                   | 0.75 (0.5–2)              | 249 (37%)                     | 2.0 (23%)        |
| Ratio to control (90% CI) | 1.48 (1.26, 1.73)           | —                         | 1.45 (1.30, 1.61)             | 1.05 (0.98, 1.13) |
| P value               | 5.37 × 10\(^{-5}\)         | 0.547                     | 3.02 × 10\(^{-8}\)           | 0.241            |
| Genotype score ≥ 2.00 |                             |                           |                               |                  |
| Geometric mean (CV%) | 235 (59%)                   | 1 (0.5–2)                 | 386 (49%)                     | 2.1 (18%)        |
| Ratio to control (90% CI) | 1.90 (1.50, 2.40)           | —                         | 2.24 (1.91, 2.63)             | 1.10 (0.99, 1.22) |
| P value               | 1.03 × 10\(^{-5}\)         | 0.400                     | 7.53 × 10\(^{-15}\)          | 0.141            |
| **3S,5R-fluvastatin** |                             |                           |                               |                  |
| Genotype score ≥0.80, ≤1.25\(^b\) |                             |                           |                               |                  |
| Geometric mean (CV%) | 145 (78%)                   | 0.5 (0.5–5)               | 175 (45%)                     | 2.5 (29%)        |
| Genotype score < 0.80 |                             |                           |                               |                  |
| Geometric mean (CV%) | 94 (93%)                    | 1 (0.5–2)                 | 125 (48%)                     | 2.3 (18%)        |
| Ratio to control (90% CI) | 0.65 (0.44, 0.97)           | —                         | 0.72 (0.55, 0.93)             | 0.90 (0.78, 1.04) |
| P value               | 0.0740                      | 0.088                     | 0.0358                        | 0.246            |
| Genotype score > 1.25, < 2.00 |                             |                           |                               |                  |
| Geometric mean (CV%) | 187 (78%)                   | 1 (0.5–2)                 | 250 (54%)                     | 2.5 (29%)        |
| Ratio to control (90% CI) | 1.30 (1.09, 1.54)           | —                         | 1.43 (1.27, 1.60)             | 1.01 (0.95, 1.08) |
| P value               | 0.0149                      | 0.009                     | 9.72 × 10\(^{-7}\)           | 0.807            |
| Genotype score ≥ 2.00 |                             |                           |                               |                  |
| Geometric mean (CV%) | 299 (23%)                   | 1 (0.5–1)                 | 573 (28%)                     | 2.4 (20%)        |
| Ratio to control (90% CI) | 2.06 (1.16, 3.68)           | —                         | 3.27 (2.23, 4.81)             | 0.96 (0.78, 1.19) |
| P value               | 0.0396                      | 0.349                     | 8.65 × 10\(^{-15}\)          | 0.762            |
| **Total fluvastatin** |                             |                           |                               |                  |
| Genotype score ≥0.80, ≤1.25\(^b\) |                             |                           |                               |                  |
| Geometric mean (CV%) | 286 (75%)                   | 1 (0.5–5)                 | 369 (46%)                     | 2.1 (32%)        |
| Genotype score > 1.25, < 2.00 |                             |                           |                               |                  |
| Geometric mean (CV%) | 378 (79%)                   | 1 (0.5–2)                 | 543 (47%)                     | 2.1 (20%)        |
| Ratio to control (90% CI) | 1.32 (1.05, 1.67)           | —                         | 1.47 (1.26, 1.71)             | 1.01 (0.91, 1.12) |
| P value               | 0.0442                      | 0.319                     | 4.88 × 10\(^{-3}\)           | 0.832            |
| Genotype score ≥ 2.00 |                             |                           |                               |                  |
| Geometric mean (CV%) | 481 (50%)                   | 1 (0.5–1.5)               | 763 (47%)                     | 2.2 (21%)        |
| Ratio to control (90% CI) | 1.68 (1.29, 2.19)           | —                         | 2.07 (1.74, 2.47)             | 1.08 (0.96, 1.22) |
| P value               | 1.26 × 10\(^{-3}\)         | 0.368                     | 1.05 × 10\(^{-10}\)          | 0.263            |

AUC\(_{0-\infty}\), area under the plasma concentration-time curve from 0 hour to infinity; CV, geometric coefficient of variation; C\(_{\text{max}}\), peak plasma concentration; t\(_{1/2}\), elimination half-life; T\(_{\text{max}}\), time to peak plasma concentration. T\(_{\text{max}}\) data are given as median (range); —, not applicable.

\(^a\)Genotype scores are the predicted relative effects of combinations of CYP2C9 and SLCO1B1 or SLCO2B1 genotypes on AUC, based on the candidate gene linear regression model. \(^b\)Control group.
Figure 3  Geometric mean (90% CI) BSA-adjusted plasma concentrations of (a) 3R,5S-fluvastatin and (c) 3S,5R-fluvastatin after a single 40 mg oral dose of racemic fluvastatin in 200 healthy volunteers with different combinations of CYP2C9 and SLCO1B1 or SLCO2B1 genotypes. The insets depict the same data on a semilogarithmic scale. The volunteers were grouped by genotype scores predicting the fold differences in \( \text{AUC}_{0-\infty} \) values between carriers of different genotype combinations and non-carriers. The right panels in (a) and (c) show the genotype scores for individuals with different genotypes. Reference genotypes are depicted with white, heterozygous with gray, and homozygous variant genotypes with black rectangles. The geometric mean ± geometric standard deviation BSA-adjusted \( \text{AUC}_{0-\infty} \) values grouped by combinations of CYP2C9 and SLCO1B1 or SLCO2B1 genotypes, as well as the genotype scores are illustrated in (b) and (d). \( \text{AUC}_{0-\infty} \), area under the plasma concentration-time curve from 0 hour to infinity; BSA, body surface area; CI, confidence interval.
homozygotes in a previous study. In our candidate gene analysis, the effect of c.521T>C on total fluvastatin was significant and larger than in the previous study. This difference may be explained by the substantially larger sample size in the present study and that the present study also included carriers of \textit{SLCO1B1} haplotypes the present study also included carriers of \textit{SLCO1B1*35} that enhance OA TP1B1 activity, e.g., \textit{SLCO1B1} haplotypes in humans. Therefore, it seems that different contributions of other transporters to the hepatic disposition of the enantiomers is the most likely explanation for the enantiospecific effects of the \textit{SLCO1B1} genotype. In addition to OATP1B1, racemic fluvastatin is a substrate of OATP1B3, OATP2B1, and sodium-dependent taurocholate cotransporting polypeptide, with the highest affinity reported for OATP2B1.

Our candidate gene analysis suggested that \textit{SLCO2B1} missense variants affect 3S,5R-fluvastatin but not 3R,5S-fluvastatin AUC. The c.1457C>T SNV, which associated with decreased 3S,5R-fluvastatin AUC, has previously been associated with decreased fenofibrate and clopidogrel AUC. In addition to \textit{SLCO2B1} SNVs, a missense SNV in \textit{SLCO2B1} associated with a minor effect on the 3R,5S/3S,5R-fluvastatin AUC ratio. It is noteworthy that the \textit{SLCO2B1} and \textit{SLCO1B3} associations were significant only when no correction for multiple testing was applied, and therefore the results should be interpreted with caution.

Although statins are generally well tolerated, they can cause muscle toxicity. The clinical spectrum of statin-induced myotoxicity ranges from mild myopathy to potentially life-threatening rhabdomyolysis. There seem to be no published studies on how the risk of myotoxicity is related to fluvastatin exposure. Because statin-induced myotoxicity is, however, generally dose-dependent and concentration-dependent, it is likely that increased systemic exposure to the active 3R,5S-fluvastatin predisposes to this adverse reaction. Both \textit{CYP2C9*3} and *2, as well as \textit{SLCO1B1} c.521T>C increase 3R,5S-fluvastatin AUC. Of these, the \textit{CYP2C9*3} allele has previously been associated with fluvastatin-induced adverse reactions. Moreover, the \textit{SLCO1B1} c.521T>C SNV increases simvastatin acid AUC more than threefold and associates with a markedly increased risk of simvastatin-induced myotoxicity.
As the effect of the c.521T>C SNV on 3R,5S-fluvastatin AUC is smaller than on simvastatin acid AUC, the increase in myotoxicity risk is also likely smaller. Markedly larger increases in 3R,5S-fluvastatin AUC are seen in individuals carrying the c.521T>C allele together with 3R,5S-fluvastatin exposure to fluvastatin. The GS might be useful in predicting the risk of fluvastatin-induced myotoxicity. For patients with 3R,5S-fluvastatin GS ≥ 2.0, it could be advisable to prescribe a lower dose of fluvastatin or consider an alternative statin.

The site of action of statins is within the hepatocytes, and fluvastatin efficacy is therefore related to the hepatocyte exposure to 3R,5S-fluvastatin. The maximum fluvastatin dose (80 mg/day) reduces Low-density lipoprotein cholesterol on average by 33%, 36 which is less than that seen with the maximum doses of rosuvastatin and atorvastatin. As the CYP2C9*3 and *2 variants impair the hepatic metabolism of fluvastatin, they should increase the hepatocyte concentration of 3R,5S-fluvastatin to at least the same extent as its plasma concentration and therefore enhance its cholesterol-lowering efficacy. Low-density lipoprotein cholesterol decreases by 6% for every twofold increase in fluvastatin dose. Therefore, individuals with, e.g., the CYP2C9*2/*3 genotype, associated with twofold increased 3R,5S-fluvastatin AUC (Figure 3), should show at least 6% greater low-density lipoprotein cholesterol-lowering efficacy of fluvastatin than individuals with the *1/*1 genotype. In one small study, there was a tendency for greater cholesterol-lowering effect of fluvastatin in patients with the CYP2C9*1/*3 genotype than in those with the *1/*1 genotype. On the other hand, the SLCO1B1 c.521T>C variant reduces the hepatic uptake of 3R,5S-fluvastatin and might thus reduce fluvastatin efficacy. In a previous study, a trend of impaired fluvastatin efficacy has been reported in c.521C allele carriers. Furthermore, the c.463C>A missense SNV, which associates with increased OATP1B1 activity, has been associated with increased cholesterol-lowering efficacy of fluvastatin. Taken together, the CYP2C9*3 and *2 alleles are expected to increase both the efficacy and the risk of myotoxicity of fluvastatin, whereas the SLCO1B1 c.521T>C allele likely increases myotoxicity risk only.

The present study was conducted in Finnish white volunteers. The frequencies of CYP2C9 and SLCO1B1 variants, however, differ between populations. The allele frequencies of CYP2C9*2, *3, and SLCO1B1 c.521T>C are 0.12, 0.056, 0.18 in Europeans, 0.024, 0.013, and 0.019 in Sub-Saharan Africans, and < 0.001, 0.034, and 0.12 in East Asians, respectively. Therefore, the extent to which these variants can explain population variability in fluvastatin pharmacokinetics differs between ethnic groups. Nevertheless, CYP2C9*2, *3, and SLCO1B1 c.521T>C are decreased-function alleles, as demonstrated both in vitro and in vivo, and individuals carrying these should have similarly increased fluvastatin exposures, irrespective of the ethnic background.

In conclusion, genetic variability in CYP2C9 significantly affects fluvastatin pharmacokinetics. In addition, SLCO1B1 genotype has an enantiospecific effect on active 3R,5S-fluvastatin pharmacokinetics. However, no obvious difference between the enantiomers was observed in the uptake by OATP1B1 in vitro. The genotype scores may predict how combinations of CYP2C9 and SLCO1B1 variants affect 3R,5S-fluvastatin exposure and aid in predicting the risk of myotoxicity.

DNA sequencing and genotyping

Genomic DNA was extracted from ethylenediaminetetraacetic acid blood samples using the Maxwell 16 LEV Blood DNA Kit on a Maxwell 16 Research automated nucleic acid extraction system (Promega, Madison, WI). A total of 379 pharmacokinetic genes ± 20 kb were parallel sequenced at the Technology Centre at Institute for Molecular Medicine Finland (Helsinki, Finland). Chromatographic separation of the enantiomers was achieved on a Lux Cellulose-1 chiral column (150 × 2.0-mm internal diameter, 3-μm particle size; Phenomenex, Torrance, CA). The mobile phase consisted of a mixture of acetonitrile, methanol and water (12:18:80 v/v/v) containing 0.01% formic acid, and the flow rate was 220 μL/min. The mass spectrometer was operated in a negative electrospray ionization mode, and the targeted mass-to-charge ratio transition for both fluvastatin enantiomers was 410–348. Deuterium-labeled fluvastatin was monitored as an internal standard. The lower limits of quantification were 0.25 ng/mL, and the inter day coefficients of variation of the quality control samples were below 7% for both enantiomers. The AUC_{0–∞}, C_{max}, and t_{1/2} values were calculated for 3R,5S-fluvastatin and 3S,5R-fluvastatin, and total fluvastatin with standard noncompartmental methods using Phoenix WinNonlin, version 6.3 (Certara, Princeton, NJ).

**Fluvastatin pharmacokinetics**

After fasting overnight, the participants ingested a 40 mg dose of racemic fluvastatin (Lescol capsule, Novartis Finland Oy, Espoo, Finland) with 150 mL of water at 8 AM. Standardized meals were served at 4, 7, and 10 hours after fluvastatin ingestion. Timed blood samples (4–9 mL each) were collected to light-protected ethylenediaminetetraacetic acid tubes prior to and up to 12 hours after fluvastatin administration. Tubes were immediately plated on ice. Plasma was separated within 30 minutes and stored at −80°C until analysis.

The determination of 3R,5S-fluvastatin and 3S,5R-fluvastatin in plasma was based on chiral liquid chromatographic-tandem mass spectrometric (LC-MS/MS) method employing commercial pure reference compounds (Toronto Research Chemicals, Inc., North York, ON). The analytical system consisted of a Nexera X2 liquid chromatography instrument (Shimadzu, Kyoto, Japan) interfaced with a 5500 Qtrap mass spectrometer (AB Sciex, Toronto, ON, Canada). Chromatographic separation of the enantiomers was achieved on a Lux Cellulose-1 chiral column (150 × 2.0-mm internal diameter, 3-μm particle size; Phenomenex, Torrance, CA). The mobile phase consisted of a mixture of acetonitrile, methanol and water (12:18:80 v/v/v) containing 0.01% formic acid, and the flow rate was 220 μL/min. The mass spectrometer was operated in a negative electrospray ionization mode, and the targeted mass-to-charge ratio transition for both fluvastatin enantiomers was 410–348. Deuterium-labeled fluvastatin was monitored as an internal standard. The lower limits of quantification were 0.25 ng/mL, and the inter day coefficients of variation of the quality control samples were below 7% for both enantiomers.

The AUC_{0–∞}, C_{max}, and t_{1/2} values were calculated for 3R,5S-fluvastatin and 3S,5R-fluvastatin, and total fluvastatin with standard noncompartmental methods using Phoenix WinNonlin, version 6.3 (Certara, Princeton, NJ).
copy number was determined with a TaqMan copy number assay targeting exon 9. CYP2D6 metabolizer status was inferred from the genotypes using the activity score method.\(^4\)

**In vitro studies with transfected OATP1B1 cells**
Recombinant baculoviruses containing reference or c.521T>C variant SLCO1B1 gene or the gene for enhanced yellow fluorescent protein (eYFP) were prepared using a modified Bac-to-Bac method.\(^3\) Human embryonic kidney 293 cells were seeded on Corning BioCoat Poly-D-Lysine 24 well plates (Corning, Woburn, MA) at a density of 250,000 cells per well and transfected with recombinant baculoviruses carrying either reference or variant SLCO1B1 gene or the eYFP gene for the control cells. Sodium butyrate (5 mM) was used to stimulate the expression of the recombinant proteins.

The cellular uptake assays were performed on a heated orbital shaker plate 48 hours post-transfection. Cell culture medium was first removed and 1 mL of transport buffer (Hank’s Balanced Salt Solution; Gibco, Thermo Fisher Scientific; 4.17 mM NaHCO3 and 25 mM HEPES adjusted to pH 7.4 with HCl) was added to wells for 3-minute preincubation. The buffer was then replaced with 250 μL of test solution, which contained 0.1, 0.5, 1, 2, 4, 8, or 16 μM (n = 2–3) of 3R,5S-fluvastatin or 3S,5R-fluvastatin for determining the transport kinetics, or 0.5 μM (n = 6) for testing the effect of c.521T>C. After 1 minute, the test solution was removed, and the wells were washed with ice-cold transport buffer three times and left to dry. Thereafter, 250 μL of methanol water mixture (3:1) containing deuterium-labeled fluvastatin was added to lyse the cells. After 30 minutes, the samples were centrifuged and the supernatant was separated for LC-MS/MS analysis.

Fluvastatin concentrations were measured with the Nexera X2 liquid chromatography-AB Sciex 5500 Qtrap mass spectrometer. The chromatographic separation was achieved on a reversed phase Kinetex C8 column (75 × 2.1-mm internal diameter, 2.6-μm particle size; Phenomenex) with a mobile phase of 0.1% formic acid (A) and acetonitrile (B). The mobile phase flow rate was 300 μL/min, with a gradient profile applied as follows: a linear increase from 25% B to 65% B over 2.5 minute, then 0.5 minute at 90% B on hold before a re-equilibration step to the starting composition. The mass spectrometric detection was performed as described for plasma samples. Dichlorofluorescein (Santa Cruz Biotechnology, Dallas, TX) was used for assay quality control in three wells expressing reference OA TP1B1 or eYFP. These wells were lysed with Biotechnology-AB Sciex 5500 Qtrap mass spectrometer. The chromatography was achieved on a reversed phase Kinetex C8 column (75 × 2.1-mm internal diameter, 2.6-μm particle size; Phenomenex) with a mobile phase of 0.1% formic acid (A) and acetonitrile (B). The mobile phase flow rate was 300 μL/min, and a gradient profile was applied as follows: a linear increase from 25% B to 65% B over 2.5 minute, then 0.5 minute at 90% B on hold before a re-equilibration step to the starting composition. The mass spectrometric detection was performed as described for plasma samples. Dichlorofluorescein (Santa Cruz Biotechnology, Dallas, TX) was used for assay quality control in three wells expressing reference OA TP1B1 or eYFP. These wells were lysed with

**Statistical analysis**
The data were analyzed with the statistical programs JMP Genomics 7.0 (SAS Institute, Inc., Cary, NC) and IBM SPSS 22.0 for Windows (Armonk, NY). The pharmacokinetic variables were logistically transformed before analysis. Sex, body weight, lean body weight,\(^7\) and body surface area\(^8\) were tested as demographic covariates for pharmacokinetic data using stepwise linear regression analysis, with P value thresholds of 0.05 for entry and 0.10 for removal. Possible effects of genetic variants on pharmacokinetic variables were investigated using linear regression analysis fixed for significant demographic covariates with a stepwise approach. A Bonferroni-corrected P value threshold of 1.09 × 10⁻⁵ was employed for the 379 genes and thresholds of 0.05 for entry and 0.10 for removal for the candidate gene analysis. Additive coding was employed for genetic variants, and multiallelic variants were expanded. CYP2D6 data were included as the activity scores in the candidate gene analysis. Haplotype computations for SLCO1B1 were performed with PHASE v2.1.1.\(^5\) Statistical comparisons of in vitro data were done using independent samples Student’s t-test, with logarithmic transformation as appropriate.

**SUPPORTING INFORMATION**
Supplementary information accompanies this paper on the Clinical Pharmacology & Therapeutics website (www.cpt-journal.com).

**Table S1.** Pharmacokinetic variables of 3R,5S-fluvastatin, 3S,5R-fluvastatin, and total fluvastatin in 200 healthy volunteers.

**Table S2.** SNVs (MAF ≥ 0.01) included in the candidate gene analysis.

**Table S3.** Results of the candidate gene analysis with SLCO1B1 haplotypes on 3R,5S-fluvastatin and 3S,5R-fluvastatin in 200 healthy volunteers.

**ACKNOWLEDGMENTS**
The authors thank Katja Halme, Hanna Hyvärinen, Satu Karjalainen, Jouko Lahtila, Eija Mäkinen-Pulli, Raija Nevala, and Lisbet Partanen for skillful assistance in conducting the clinical pharmacokinetic study, and Pekka Eilonen and Maija Lepistö, for the massive parallel sequencing.

**FUNDING**
This study was supported by grants from the European Research Council (Grant agreement 282106), State funding for university-level health research, and the Sigrid Juselius Foundation (Helsinki, Finland).

**CONFLICTS OF INTEREST**
The authors declared no competing interests for this work.

**AUTHOR CONTRIBUTIONS**
P.H. and M.Ni. wrote the manuscript; P.H., A.T., J.T.B., and M.Ni. designed the research; P.H., A.T., M.Ne., W.K., T.T., M.P.H., H.K., J.T.B., and M.Ni. performed the research; P.H. and M.Ni. analyzed the data.

© 2019 The Authors Clinical Pharmacology & Therapeutics published by Wiley Periodicals, Inc. on behalf of American Society for Clinical Pharmacology and Therapeutics

This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.
1. Kathawala, F.G. HMG-CoA reductase inhibitors: an exciting development in the treatment of hyperlipoproteinemia. Med. Res. Rev. 11, 121–146 (1991).

2. Fischer, V. et al. The 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor fluvastatin: effect on human cytochrome P-450 and implications for metabolic drug interactions. Drug Metab. Dispos. 27, 410–416 (1999).

3. Neuvonen, P.J., Niemi, M. & Backman, J.T. Drug interactions with lipid-lowering drugs: mechanisms and clinical relevance. Clin. Pharmacol. Ther. 80, 565–581 (2006).

4. Kopplow, K., Letschert, K., König, J., Walter, B. & Keppler, D. Human hepatobiliary transport of organic anions analyzed by quadrupole-transfected cells. Mol. Pharmacol. 68, 1031–1038 (2005).

5. Hirano, M., Maeda, K., Matsushima, S., Nozaki, Y., Kusuhara, H. & Sugiyama, Y. Involvement of BCRP (ABCG2) in the biliary excretion of pravastatin. Mol. Pharmacol. 68, 800–807 (2005).

6. Kalliokoski, A. & Niemi, M. Impact of OATP transporters on pharmacokinetics. Br. J. Pharmacol. 158, 693–705 (2009).

7. Greupink, R., Dillen, L., Monshouwer, M., Huisman, M.T. & Russel, F.G. Interaction of fluvastatin with the liver-specific Na+-dependent taurocholate cotransporting polypeptide (NTCP). Eur. J. Pharm. Sci. 44, 487–496 (2011).

8. Ellis, L.C., Hawksworth, G.M. & Weaver, R.J. ATP-dependent transport of statins by human and rat MRP2/MRP2. Toxicol. Appl. Pharmacol. 269, 187–194 (2013).

9. Haining, R.L., Hunter, A.P., Veronese, M.E., Trager, W.F. & Rettie, A.E. Allelic variants of human cytochrome P450 2C9: baculovirus-mediated expression, purification, structural characterization, substrate stereoselectivity, and prochiral selectivity of the wild-type and I359L mutant forms. Arch. Biochem. Biophys. 333, 447–458 (1996).

10. Daly, A.K., Rettie, A.E., Fowler, D.M. & Miners, J.O. Pharmacogenomics of CYP2C9: functional and clinical considerations. J. Pers. Med. 8 (2017) https://doi.org/10.3390/jpm8010001.

11. Kircheiner, J. et al. Influence of CYP2C9 polymorphisms on the pharmacokinetics and cholesterol-lowering activity of (−)-3S,5R-fluvastatin and (+)-3R,5S-fluvastatin in healthy volunteers. Clin. Pharmacol. Ther. 74, 186–194 (2003).

12. Kondo, C. et al. Functional analysis of SNPs variants of BCRP/ABCG2. Pharm. Res. 21, 1895–1903 (2004).

13. Keskiotalo, J.E., Zolk, O., Fromm, M.F., Kurkinen, K.J., Neuvonen, P.J. & Niemi, M. ABCG2 polymorphism markedly affects the pharmacokinetics of fluvastatin, pravastatin and simvastatin. Pharmacogenomics 10, 1617–1624 (2009).

14. Giacomini, K.M. et al. International Transporter Consortium commentary on clinically important transporter polymorphisms. Clin. Pharmacol. Ther. 94, 23–28 (2013).

15. Tirona, R.G., Leake, B.F., Merino, G. & Kim, R.B. Polymorphisms in OATP-C: identification of multiple allelic variants associated with altered transport activity among European- and African-Americans. J. Biol. Chem. 276, 35669–35675 (2001).

16. Nishizato, Y. et al. Polymorphisms of OATP-C (SLC21A6) and OAT3 (SLC22A8) genes: consequences for pravastatin pharmacokinetics. Clin. Pharmacol. Ther. 73, 554–565 (2003).

17. Niemi, M. et al. High plasma pravastatin concentrations are associated with single nucleotide polymorphisms and haplotypes of organic anion transporting polypeptide-C (OATP-C, SLC01B1). Pharmacogenetics 14, 429–440 (2004).

18. Mwiyni, J., John, A., Bauer, S., Roots, I. & Gerloff, T. Evidence for inverse effects of OATP-C (SLC21A6) 5 and 1b haplotypes on pravastatin kinetics. Clin. Pharmacol. Ther. 75, 415–421 (2004).

19. Pasanen, M.K., Neuvonen, P.J. & Niemi, M. SLCO1B1 polymorphism markedly affects the pharmacokinetics of simvastatin acid. Pharmacogenet. Genomics 16, 873–879 (2006).

20. Niemi, M., Pasanen, M.K. & Neuvonen, P.J. SLC01B1 polymorphism and sex affect the pharmacokinetics of pravastatin but not fluvastatin. Clin. Pharmacol. Ther. 80, 356–366 (2006).

21. Niemi, M., Pasanen, M.K. & Neuvonen, P.J. Organic anion transporting polypeptide 1B1: a genetically polymorphic transporter of major importance for hepatic drug uptake. Pharmacol. Rev. 63, 157–181 (2011).

22. Tornio, A., Vakkilainen, J., Neuvonen, M., Backman, J.T., Neuvonen, P.J. & Niemi, M. SLC01B1 polymorphism markedly affects the pharmacokinetics of lovastatin acid. Pharmacogenet. Genomics 25, 382–387 (2015).

23. Keskiotalo, J.E., Kurkinen, K.J., Neuvonen, M., Backman, J.T., Neuvonen, P.J. & Niemi, M. No significant effect of ABCB1 haplotypes on the pharmacokinetics of fluvastatin, pravastatin, lovastatin, and rosuvastatin. Br. J. Clin. Pharmacol. 68, 207–213 (2009).

24. Baldwin, S.J., Bloomer, J.C., Smith, G.J., Ayrton, A.D., Clarke, S.E. & Chenery, R.J. Ketoconazole and sulphaphenazole as the respective selective inhibitors of P4503A and 2C9. Xenobiotica 25, 261–270 (1995).

25. Rettie, A.E., Wienkers, L.C., Gonzalez, F.J., Trager, W.F. & Korzekwa, K.R. Impaired (S)-warfarin metabolism catalysed by the R144C allelic variant of CYP2C9. Pharmacogenetics 4, 39–42 (1994).

26. Nies, A.T. et al. Genetics is a major determinant of expression of the human hepatic uptake transporter OATP1B1, but not of OATP1B3 and OATP2B1. Genome Med. 5 (2013) https://doi.org/10.1186/gm405.

27. Ramsey, L.B. et al. Rare versus common variants in pharmacogenetics; SLC01B1 variation and methotrexate disposition. Genome Res. 22, 1–8 (2012).

28. Weiner, M. et al. Effects of tuberculosis, race, and human gene SLC01B1 polymorphisms on rifampin concentrations. Antimicrob. Agents Chemother. 54, 4192–4200 (2010).

29. Imanaga, J. et al. The effects of the SLC02B1 c.1457C > T polymorphism and apple juice on the pharmacokinetics of fexofenadine and midazolam in humans. Pharmacogenet. Genomics 21, 84–93 (2011).

30. Ireri, I. et al. Microdosing clinical study: pharmacokinetic, pharmacogenomic (SLC02B1), and interaction (grapefruit juice) profiles of celiprolol following the oral microdose and therapeutic dose. J. Clin. Pharmacol. 52, 1078–1089 (2012).

31. Alfinrajovic, A. et al. Phenotype standardization for statin-induced myotoxicity. Clin. Pharmacol. Ther. 96, 470–476 (2014).

32. Thompson, P.D., Clarkson, P. & Karas, R.H. Statin-associated myopathy. JAMA 289, 1681–1690 (2003).

33. Miroševic Skvrce, N., Božina, N., Zibar, L., Barišic, I., Pejnovic, L. & Macolic Šarinic, V. CYP2C9 and ABCG2 polymorphisms as risk factors for developing adverse drug reactions in renal transplant patients taking fluvastatin: a case-control study. Pharmacogenomics 14, 1419–1431 (2013).

34. SEARCH Collaborative Group SLC01B1 variants and statin-induced myopathy—a genomewide study. N. Engl. J. Med. 359, 789–799 (2008).

35. Adams, S.P., Sekhon, S.S., Tsang, M. & Wright, J.M. Fluvastatin for lowering lipids. Cochrane Database Syst. Rev. 3, CD012282 (2018).

36. Buzková, H. et al. Lipid-lowering effect of fluvastatin in relation to cytochrome P450 2C9 variant alleles frequently distributed in the Czech population. Med. Sci. Monit. 18, S12–S17 (2012).

37. Meyer zu Schwabedissen, H.E. et al. Function-impairing polymorphisms of the hepatic uptake transporter SLC01B1 modify the therapeutic efficacy of statins in a population-based cohort. Pharmacogenet. Genomics 25, 8–18 (2015).

38. Couvert, P. et al. Association between a frequent allele of the gene encoding OATP1B1 and enhanced LDL-lowering response to fluvastatin therapy. Pharmacogenomics 9, 1217–1227 (2008).

39. Pasanen, M.K., Neuvonen, P.J. & Niemi, M. Global analysis of genetic variation in SLC01B1. Pharmacogenomics 9, 19–33 (2008).
41. Zhou, Y., Ingelman-Sundberg, M. & Lauschke, V.M. Worldwide distribution of cytochrome P450 alleles: a meta-analysis of population-scale sequencing projects. Clin. Pharmacol. Ther. 102, 688–700 (2017).
42. Hirvensalo, P. et al. Comprehensive pharmacogenomic study reveals an important role of UGT1A3 in montelukast pharmacokinetics. Clin. Pharmacol. Ther. 104, 158–168 (2018).
43. Sulonen, A.M. et al. Comparison of solution-based exome capture methods for next generation sequencing. Genome Biol. 12, R94 (2011).
44. Gonçalves, B.P. et al. Age, weight, and CYP2D6 genotype are major determinants of primaquine pharmacokinetics in African children. Antimicrob. Agents Chemother. 61, e02590-16 (2017).
45. Gaedigk, A., Simon, S.D., Pearce, R.E., Bradford, L.D., Kennedy, M.J. & Leeder, J.-S. The CYP2D6 activity score: translating genotype information into a qualitative measure of phenotype. Clin. Pharmacol. Ther. 83, 234–242 (2008).
46. Sjöstedt, N., van den Heuvel, J.J.M.W., Koenderink, J.B. & Kidron, H. Transmembrane domain single-nucleotide polymorphisms impair expression and transport activity of ABC transporter ABCG2. Pharm. Res. 34, 1626–1636 (2017).
47. Hallynck, T.H., Soep, H.H., Thomis, J.A., Boelaert, J., Daneels, R. & Dettli, L. Should clearance be normalised to body surface or to lean body mass? Br. J. Clin. Pharmacol. 11, 523–526 (1981).
48. Haycock, G.B., Schwartz, G.J. & Wisotsky, D.H. Geometric method for measuring body surface area: a height-weight formula validated in infants, children, and adults. J. Pediatr. 93, 62–66 (1978).
49. Stephens, M., Smith, N.J. & Donnelly, P. A new statistical method for haplotype reconstruction from population data. Am. J. Hum. Genet. 68, 978–989 (2001).
50. Stephens, M. & Donnelly, P. A comparison of bayesian methods for haplotype reconstruction from population genotype data. Am. J. Hum. Genet. 73, 1162–1169 (2003).